

Meet The Professor: Optimizing the Management of Ovarian Cancer —  
Part 1 of a 5-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the duration of treatment with olaparib and with niraparib in the Phase III SOLO-1 and PRIMA trials, respectively, evaluating those agents as maintenance therapy after debulking surgery and first-line platinum-based chemotherapy?**
  - Two years for both
  - Three years for both
  - Two years for olaparib, 3 years for niraparib
  - Two years for niraparib, 3 years for olaparib
- 2. In the Phase III PAOLA-1 study the addition of olaparib to bevacizumab as first-line maintenance therapy for advanced ovarian cancer resulted in an improvement in progression-free survival (PFS) in which of the following subgroups?**
  - Patients with tumor BRCA mutations
  - Patients without tumor BRCA mutations
  - Patients with homologous recombination deficiency (HRD)-positive tumors, including those with BRCA mutations
  - Patients with HRD-positive tumors without BRCA mutations
  - All of the above subgroups
- 3. The ongoing Phase III DUO-O trial is evaluating durvalumab with platinum-based chemotherapy and bevacizumab followed by which of the following maintenance regimens for patients with newly diagnosed advanced ovarian cancer?**
  - Durvalumab
  - Bevacizumab/niraparib
  - Durvalumab/ramucirumab/rucaparib
  - Durvalumab/bevacizumab/olaparib
- 4. Which of the following patients with advanced ovarian cancer derived the greatest PFS benefit in the Phase II OVARIO trial evaluating niraparib/bevacizumab after first-line bevacizumab/platinum chemotherapy?**
  - Those with homologous recombination-deficient (HRd) tumors
  - Those with homologous recombination-proficient (HRp) tumors
  - Outcomes were equivalent for patients with HRd and HRp tumors
- 5. Which of the following best describes the target of the novel antibody-drug conjugate upifitamab rilsodotin currently under investigation for patients with ovarian cancer?**
  - Folate receptor alpha
  - NaPi2b
  - Tissue factor
  - TROP2